JPS6422874A - Amorphos aztreonum - Google Patents

Amorphos aztreonum

Info

Publication number
JPS6422874A
JPS6422874A JP63162369A JP16236988A JPS6422874A JP S6422874 A JPS6422874 A JP S6422874A JP 63162369 A JP63162369 A JP 63162369A JP 16236988 A JP16236988 A JP 16236988A JP S6422874 A JPS6422874 A JP S6422874A
Authority
JP
Japan
Prior art keywords
aztreonum
amorphos
methylethoxy
ami
imino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63162369A
Other languages
English (en)
Other versions
JP2701869B2 (ja
Inventor
Amiraru Baria Saireshiyu
Yuujin Reia Jiyooji
Dagurasu Pipukin Jieemusu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of JPS6422874A publication Critical patent/JPS6422874A/ja
Application granted granted Critical
Publication of JP2701869B2 publication Critical patent/JP2701869B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP63162369A 1987-07-01 1988-06-29 非晶形のアズトレオナム Expired - Lifetime JP2701869B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6839287A 1987-07-01 1987-07-01
US68,392 1987-07-01

Publications (2)

Publication Number Publication Date
JPS6422874A true JPS6422874A (en) 1989-01-25
JP2701869B2 JP2701869B2 (ja) 1998-01-21

Family

ID=22082279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63162369A Expired - Lifetime JP2701869B2 (ja) 1987-07-01 1988-06-29 非晶形のアズトレオナム

Country Status (9)

Country Link
EP (1) EP0297580B1 (ja)
JP (1) JP2701869B2 (ja)
KR (1) KR890002141A (ja)
CN (1) CN1028234C (ja)
AT (1) ATE175965T1 (ja)
CA (1) CA1339136C (ja)
DE (1) DE3856297T2 (ja)
ES (1) ES2127178T3 (ja)
GR (1) GR3029873T3 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137474A1 (ja) * 2005-06-23 2006-12-28 Eisai R & D Management Co., Ltd. ４－（３－クロロ－４－（シクロプロピルアミノカルボニル）アミノフェノキシ）－７－メトキシ－６－キノリンカルボキサミドの塩のアモルファスおよびその製造方法
JP2007521306A (ja) * 2003-07-02 2007-08-02 コーラス ファーマ，インコーポレイティド アズトレオナムｌ−リジン及びそれを調製するための方法
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
CN101912356A (zh) * 2010-08-02 2010-12-15 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
WO2014098176A1 (ja) * 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191492B (ja) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
ES2282299T3 (es) 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
US7138419B2 (en) 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
DE122011100043I1 (de) 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
KR100687001B1 (ko) 2002-08-05 2007-02-27 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 아즈트레오남의 제법
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
CN1802371A (zh) 2003-05-15 2006-07-12 特瓦药厂有限公司 残余溶剂含量极低的阿兹托南β多晶型
JP4648835B2 (ja) 2003-12-25 2011-03-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法
EP1888576B1 (en) 2005-05-09 2009-02-18 Sicor Inc. Process for making aztreonam
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101579336B (zh) * 2009-07-07 2010-06-23 重庆市庆余堂制药有限公司 一种注射用氨曲南及其生产方法
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5823689A (ja) * 1981-07-13 1983-02-12 イ−・ア−ル・スクイブ・アンド・サンズ・インコ−ポレイテツド 置換アゼチジノン誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5823689A (ja) * 1981-07-13 1983-02-12 イ−・ア−ル・スクイブ・アンド・サンズ・インコ−ポレイテツド 置換アゼチジノン誘導体

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
JP2007521306A (ja) * 2003-07-02 2007-08-02 コーラス ファーマ，インコーポレイティド アズトレオナムｌ−リジン及びそれを調製するための方法
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
JP4733700B2 (ja) * 2005-06-23 2011-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩のアモルファスおよびその製造方法
WO2006137474A1 (ja) * 2005-06-23 2006-12-28 Eisai R & D Management Co., Ltd. ４－（３－クロロ－４－（シクロプロピルアミノカルボニル）アミノフェノキシ）－７－メトキシ－６－キノリンカルボキサミドの塩のアモルファスおよびその製造方法
CN101912356A (zh) * 2010-08-02 2010-12-15 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JPWO2014098176A1 (ja) * 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
WO2014098176A1 (ja) * 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10822307B2 (en) 2014-08-28 2020-11-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11186547B2 (en) 2014-08-28 2021-11-30 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
KR890002141A (ko) 1989-04-08
GR3029873T3 (en) 1999-07-30
DE3856297D1 (de) 1999-03-04
DE3856297T2 (de) 1999-06-02
CN1030238A (zh) 1989-01-11
EP0297580B1 (en) 1999-01-20
EP0297580A1 (en) 1989-01-04
ES2127178T3 (es) 1999-04-16
CA1339136C (en) 1997-07-29
JP2701869B2 (ja) 1998-01-21
ATE175965T1 (de) 1999-02-15
CN1028234C (zh) 1995-04-19

Similar Documents

Publication Publication Date Title
JPS6422874A (en) Amorphos aztreonum
CA2418125A1 (en) Beta-lactams useful in the preparation of substituted isoserine esters
CA2035972A1 (en) Process for the preparation of oxetanones
HU913283D0 (en) Process for the production of hydroximethyl-(methylene-cyclopentyl)-purines and pirimidines, their medically usable salts, and of medical preparations containing them
IL88755A (en) (1:, 2, 3:)-3-substituted-2- hydroxycyclo- butanemethanol derivatives and pharmaceutical and veterinary compositions containing the same
AU7493187A (en) Cephalosporin compounds, processes for their preparation and antibacterial agents
AU7194991A (en) Macrolide pharmaceutical solutions
AU557096B2 (en) Thiazole derivatives
YU117185A (en) Process for obtaining 2-substituted-1,3 propyl of idenediphosphonate derivatives
EP0177940A3 (en) Hydrazine derivatives and their use
IL74066A0 (en) 6,6-ethylene-15,16-methylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactones,processes for the production thereof,and pharmaceutical preparations containing them
MY104063A (en) Crystalline (beta)-lactam hydrate
AU2037088A (en) Naphthyridine antianaerobic compounds
CA1271748C (en) BENZAZEPINE DERIVATIVES
EP0342423A3 (en) Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
AU584270B2 (en) Novel derivatives of erythromycylamine
SE8705068L (sv) Kristallina salter av /3s(z)/-2-///1-(2-amino-4-tiazolyl)-2-//2,2-dimetyl-4-oxo-1-(sulfooxi)-3-azetidinyl/-amino/-2-oxoetyliden/-amino/oxi/ettiksyra
EP0276393A3 (en) Process for the preparation of 6-alpha, 9-alpha-difluoro-11-beta-17-alpha-dihydroxy-16-alpha-methyl-pregn-4-ene-3,20-dione and its derivatives
ES2012564A6 (es) Un procedimiento para preparar un glicosido de antraciclina.
ES2004384A6 (es) Procedimiento para preparar compuestos antibioticos macrolidos y metodo para combatir plagas con ellos.
USD284675S (en) Drafting instrument
HU912216D0 (en) Process for the production of purinyl-and pirimidinyl - tetrahydrofurane derivatives and medical preparations containing them
DE3270516D1 (en) Thiophene derivative having a mucoregulating and anticough activity, process for its preparation and pharmaceutical compositions containing it
CA2011668A1 (en) Germicidal composition
EP0266426A4 (en) PSEUDOURIDINE DERIVATIVE.